<DOC>
	<DOCNO>NCT00003289</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness UCN-01 treating patient advance cancer respond previous treatment .</brief_summary>
	<brief_title>UCN-01 Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity profile , dose limit toxicity , maximum tolerate dose UCN-01 administer 3 , 2 , 1 hour infusion every 4 week patient advance solid tumor malignancy chronic lymphoproliferative disorder . II . Investigate pharmacokinetics cellular pharmacodynamics UCN-01 administered schedule patient . III . Obtain preliminary evidence antitumor activity UCN-01 patient population . OUTLINE : This dose escalation study . Patients receive UCN-01 intravenous infusion 3 , 2 1 hour ( ) every 4 week . The first dose level administer 3 hour , next dose level administer 2 hour , next subsequent dose level administer 1 hour . One patient treat dose level unacceptable toxicity observe . An additional 2 patient enter dose level . If dose limit toxicity ( DLT ) experience 1 3 patient , 3 additional patient accrue dose level . If 2 patient experience DLT , maximum tolerate dose surpass total 6 patient must treat previous dose level . If patient develop DLT , dose escalate successive cohort 3 patient per dose level . Patients follow 4 week drug administration subsequent patient enter next high dose level . Patients follow 2 month last dose UCN-01 . PROJECTED ACCRUAL : Approximately 36 patient accrue study 18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>7-hydroxystaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy refractory standard therapy standard therapy exist Low grade lymphoproliferative disorder define : Chronic lymphocytic leukemia/small lymphocytic lymphoma Waldenstrom 's macroglobulinemia Follicular lymphoma ( small cleave , mixed , large cell ) Mantle cell lymphoma Prolymphocytic leukemia ( T B type ) Cutaneous T cell nonHodgkin 's lymphoma Marginal zone lymphoma variant Hairy cell leukemia variant MALT lymphomas Patients low grade lymphoproliferative disorder must receive least 1 treatment regimen must eligible potentially curative treatment ( i.e. , bone marrow transplantation ) No HTLV1 associate lymphoma , Burkitt 's small noncleaved lymphoma , transplant relate lymphoproliferative disorder , Hodgkin 's disease , diffuse large cell lymphoma , multiple myeloma No primary brain tumor history brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hemoglobin least 8.0 g/dL Hepatic : Bilirubin great 1.2 mg/dL AST/ALT le 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No history unstable newly diagnose angina pectoris No myocardial infarction within last 6 month No New York Heart Association class IIIV congestive heart failure Neurologic : No grade 2 great peripheral neuropathy Pulmonary : No grade 2 great pulmonary toxicity ( dyspnea significant exertion ) Other : HIV negative No autoimmune hemolytic anemia Must able central venous access catheter No active infection require oral intravenous antibiotic No medical psychiatric problem unrelated malignancy may limit compliance study , expose patient undue risk , confound toxicity assessment Not pregnant nursing Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 month since prior platelet red blood cell transfusion Chemotherapy : At least 6 week since nitrosoureas mitomycin At least 4 week since chemotherapy No investigational standard chemotherapy least 2 month completion last dose UCN01 Endocrine therapy : Not specify Radiotherapy : At least 4 week since radiotherapy Surgery : At least 4 week since major surgery Other : No concurrent anticonvulsant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>